Reparixin 1200 mg TID as add-on to SoC to Limit Disease Progression in Hospitalised Patients With COVID-19 and Other Community-Acquired Pneumonia. A Multicentre, Randomised, Double-blinded, Placebo-controlled, Phase III Trial (REPAVID-22)

Protocol No
PULM-DOMPE-REPAVID-22
Staff Member
Rahul Nanchal
Phase
III
Summary

This project is being done to see how well Reparixin works in stopping or reducing symptoms of COVID-19 and other community- acquired pneumonia (CAP) in hospitalized patients.

Objective
Reparixin as add-on to SOC to Limit Disease Progression in COVID-19 and Pneumonia
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL